Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
The aim of this study was to investigate the efficacy and safety of S-1 plus low-dose cisplatin for stage IIIB and stage IIIC gastric cancer patients after D2 gastrectomy.



The study group comprised of 52 patients. In the first cycle, S-1 (80 mg/m2) was administered daily for 3 weeks, followed by 2 weeks of rest; low-dose cisplatin (10 mg) was administered on days 1-5 and 8-12. In the second and third cycles, S-1 was administered alone.



Overall survival was 47.0 months for stage IIIB patients and 24.0 months for stage IIIC (p=0.038). Disease-free survival was 17.0 and 16.0 months respectively (p=0.739). Grade 3 or 4 adverse events occurred in 20 patients (38.5%). Multivariate analysis identified stage IIIC as independent prognostic factor for survival.



Our treatment was manageable and safe for stage IIIB or stage IIIC patients. Stage IIIC gastric cancer portends an especially poor prognosis following D2 gastrectomy.
Department of Surgery, New Tokyo Hospital, Chiba, Japan k-mita01@sth-medical.co.jp.
Kazuhito
K
Mita
Department of Surgery, New Tokyo Hospital, Chiba, Japan.
Hideto
H
Ito
Department of Surgery, New Tokyo Hospital, Chiba, Japan.
Emi
E
Ota
Department of Surgery, New Tokyo Hospital, Chiba, Japan.
Koudai
K
Takahashi
Department of Surgery, New Tokyo Hospital, Chiba, Japan.
Masatoshi
M
Hashimoto
Department of Surgery, New Tokyo Hospital, Chiba, Japan.
Hideki
H
Asakawa
Department of Surgery, New Tokyo Hospital, Chiba, Japan.
Takashi
T
Hayashi
Department of Surgery, New Tokyo Hospital, Chiba, Japan.
Keiichi
K
Fujino
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010094:Oxonic Acid / Q000008:administration & dosage*; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D005641:Tegafur / Q000008:administration & dosage*; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin
S-1; Stage III; adjuvant chemotherapy; cisplatin; gastric cancer